Last update 01 Nov 2024

The HIV Netherlands Australia Thailand Research Collaboration

Thailand

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with The HIV Netherlands Australia Thailand Research Collaboration

NCT05930730 / RecruitingPhase 2IIT

A Phase 2, Non-inferiority, Open-label, Randomized Controlled Study to Evaluate the Immunogenicity and Safety of Comvigen (Bivalent) Vaccine as a Booster Dose in Adults Who Have Received a Previous Booster Dose of an Approved COVID-19 Vaccine

This study will assess the safety, reactogenicity and immunogenicity of a single dose of Comvigen (Bivalent, ChulaCov19 BNA159.2) vaccine or BIVALENT Pfizer/BNT vaccine as a booster among healthy males and non-pregnant females aged 18-64 years after receiving a previous booster dose of any approved mRNA COVID-19 vaccine for more than 3 months. The results of Combiven will be compared to BIVALENT Pfizer/BNT vaccine.

Start Date09 Oct 2023

Sponsor / Collaborator

University of Chulalongkorn

[+1]

NCT05350865 / RecruitingNot ApplicableIIT

Prevalence, Risk Factor and Clinical Significance of Hepatitis D Virus Infection Among Targeted High Risk Population in Thailand: Nationwide Survey 2022-2024

There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment

Start Date30 Jan 2023

Sponsor / Collaborator

The HIV Netherlands Australia Thailand Research Collaboration

[+5]

NCT04552015 / TerminatedNot ApplicableIIT

Pilot Study for Development of Microneedles for Diagnosis of Latent Tuberculosis Infection

This study will evaluate new technique, microneedle, to detect latent tuberculosis (TB) in healthy volunteers

Start Date08 Apr 2021

Sponsor / Collaborator

The HIV Netherlands Australia Thailand Research Collaboration

100 Clinical Results associated with The HIV Netherlands Australia Thailand Research Collaboration

0 Patents (Medical) associated with The HIV Netherlands Australia Thailand Research Collaboration

184

Literatures (Medical) associated with The HIV Netherlands Australia Thailand Research Collaboration

01 Nov 2024·AIDS

Epicardial fat tissue and diastolic dysfunction in both men and women with HIV

Article

Author: Tumkosit, Monravee ; Chattranukulchai, Pairoj ; Apornpong, Tanakorn ; Han, Win Min ; Avihingsanon, Anchalee

09 Jul 2024·Antimicrobial Agents and Chemotherapy

Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment

Article

Author: Salvadori, Nicolas ; Cressey, Tim R. ; Thongsawat, Satawat ; Swanson, Alistair ; Ribeiro, Isabela ; Tan, Soek-Siam ; Thanprasertsuk, Sombat ; Panjasawatwong, Navarat ; Gillon, Jean-Yves ; Menétrey, Caroline ; Avihingsanon, Anchalee

ABSTRACTRavidasvir (RDV) is a novel NS5A inhibitor that exhibits potent pan-genotypic inhibition of hepatitis C virus (HCV) replication. Sofosbuvir (SOF) plus RDV was demonstrated to be efficacious and safe in adults with active HCV infection, including those living with HIV (LWHIV), in the STORM-C-1 trial. We assessed the population pharmacokinetics (PK) of RDV in a sub-study nested within STORM-C-1 conducted in Thailand and Malaysia. SOF (400 mg) plus RDV (200 mg) was administered orally once daily for 12 weeks to adults with chronic HCV infection, but without cirrhosis and for 24 weeks to those with compensated cirrhosis. Intensive and sparse PK samples were collected at 4, 8, and 12 weeks after treatment initiation. Population PK parameters of RDV and the impact of covariates were evaluated using nonlinear mixed-effects modeling. Five hundred ninety-four participants were included, 235 (40%) had compensated cirrhosis, and 189 (32%) were LWHIV. RDV plasma concentrations were best described by a two-compartment model with first-order elimination. Oral clearance (CL/F) and volume of distribution (Vd/F) parameters were allometrically scaled on fat-free mass. Concomitant antiretroviral treatment (ART) increased RDV CL/F by 30%–60%, with efavirenz-based ART having the largest impact. Females had 16% lower RDV CL/F than males, and higher albumin levels reduced RDV central volume of distribution. While several covariates impact RDV CL/F and Vd/F, the effect on RDV exposures was not clinically relevant based on the efficacy data reported in this diverse Asian adult population. There were no meaningful drug-drug interactions in adults LWHIV on ART.

01 May 2024·Journal of Hypertension

HIGH PREVALENCES OF NOCTURNAL HYPERTENSION AND ISOLATED NOCTURNAL HYPERTENSION IN LONG-STANDING VIRALLY SUPPRESSED PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS

Author: Avihingsanon, Anchalee ; Chattranukulchai, Pairoj ; Nakornchai, Gahn ; Kositanurit, Weerapat ; Suksiriworaboot, Tanawin

Objective:Nocturnal hypertension (NH) and isolated nocturnal hypertension (INH) have emerged as residual risks for adverse cardiovascular events. Little is known about the prevalence among virally suppressed people living with human immunodeficiency virus (PLHIV) without a known history of hypertension (HT).Design and method:A cross-sectional study was conducted among virally suppressed PLHIV without a known history of HT who had normotensive office blood pressure (BP). All participants underwent 24-hour ambulatory blood pressure monitoring (ABPM). Blood pressure phenotypes were analyzed according to the 2023 ESH guidelines for the management of arterial HT. Normotension was defined as a 24-hour average BP <130/80 mmHg, NH as a nighttime BP greater than or equal to 120/70 mmHg, INH as NH but with normal both office BP (<140/90 mmHg) and daytime BP (<135/85 mmHg), and non-dipping as a drop of nighttime systolic/diastolic BP <10% compared to daytime systolic/diastolic BP.Results:A total of 83 participants were included with a mean age of 52.5±7.8 years (61.4% women). The mean duration of viral load suppression was 14.2±5.9 years. Overall, 67 participants (80.7%) were confirmed normotension by ABPM. The prevalences of NH and INH were 29% and 18.1%, respectively. Around half of the participants had non-dipping systolic BP (56.6%) and non-dipping diastolic BP (49.4%). Moreover, non-dipping diastolic BP was a significant predictor of NH in multivariable logistic regression analysis (OR 9.54, 95%CI 1.05-86.29; p=0.045).Conclusions:In this long-standing, well-suppressed PLHIV with normotensive office BP, the prevalences of NH and INH were high. Non-dipping diastolic BP might be a good predictor of NH in this population.

100 Deals associated with The HIV Netherlands Australia Thailand Research Collaboration

100 Translational Medicine associated with The HIV Netherlands Australia Thailand Research Collaboration

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

The HIV Netherlands Australia Thailand Research Collaboration

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing